50901-43-4

Basic information

• Product Name: 4-Pyridazinemethanol
• Synonyms: 4-Pyridazinemethanol;pyridazin-4-ylMethanol
• CAS NO: 50901-43-4
• Molecular Formula: C₅H₆N₂O
• Molecular Weight: 110.115
• Mol File: 50901-43-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 325.731°C at 760 mmHg
• Flash Point: 150.797°C
• Appearance: /
• Density: 1.228g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.557
• Storage Temp.: 2-8°C
• PKA: 13.24±0.10(Predicted)
• CAS DataBase Reference: 4-Pyridazinemethanol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridazinemethanol(50901-43-4)
• EPA Substance Registry System: 4-Pyridazinemethanol(50901-43-4)

Safety Data

• Hazardous Substances Data: 50901-43-4(Hazardous Substances Data)

Usage

General Description

4-Pyridazinemethanol, also known as Pyridazine-4-methanol or 4-hydroxymethylpyridazine, is an organic chemical compound. It is classified under various categories such as Alcohols, Hydroxyl Compounds, Pyridazines, and Pyridazine alcohols. Its molecular formula is C5H6N2O, and it is noted for its ring structure; more specifically, it contains a pyridazine ring, which is a six-membered aromatic ring compound consisting of four carbon atoms, two nitrogen atoms, and is often utilized in pharmaceuticals. Its appearance is often described as a clear, light yellow to orange liquid. It is used extensively in research and has potential applications in various industries, including pharmaceuticals, agriculture, and material science. However, its impact on environment and health is evaluated based on its concentration and exposure levels.

InChI:InChI=1/C5H6N2O/c8-4-5-1-2-6-7-3-5/h1-3,8H,4H2

Upstream product

• 39123-39-2 ethyl pyridazine-4-carboxylate 
• 39816-19-8 4-styrylpyridazine 
• 1120-88-3 4-methylpyridazine 
• 35782-28-6 trans-4-styrylpyridazine 
• 50681-25-9 pyridazine-4-carboxylic acid 
• 34231-77-1 methyl pyridazine-4-carboxylate 

Downstream Products

• 165558-81-6 methyl(pyridazinylmethyl)amine 
• 165558-66-7 5--8-nitronaphthalene-1-carbonitrile 
• 215298-87-6 5-(2-n-propoxyphenyl)-3-n-propyl-2-(pyridazin-4-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one 

Relevant articles and documents

An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders

A set of novel Kv7.2/7.3 (KCNQ2/3) channel blockers was synthesized to address several liabilities of the known compounds XE991 (metabolic instability and CYP inhibition) and the clinical compound DMP 543 (acid instability, insolubility, and lipophilicity). Using the anthrone scaffold of the prior channel blockers, alternative heteroarylmethyl substituents were installed via enolate alkylation reactions. Incorporation of a pyridazine and a fluorinated pyridine gave an analog (compound 18, JDP-107) with a promising combination of potency (IC50 = 0.16 μM in a Kv7.2 thallium flux assay), efficacy in a Kv7.2/7.3 patch clamp assay, and drug-like properties.

Novel HIV reverse transcriptase inhibitors

The invention is related to compounds of Formula (I), (II), or (III): or a pharmaceutically acceptable salt, solvate, ester, and/or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

Inhibitors of protein isoprenyl transferases

Compounds having the formula STR1or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 --, and (i) heterocyclic-L 2 --; R 2 is selected from STR2(b) --C(O)NH--CH(R 14)--C(O)OR 15, STR3(d) --C(O)NH--CH(R 14)--C(O)NHSO 2 R 16, (e) --C(O)NH--CH(R 14)-tetrazolyl, (f) --C(O)NH-heterocyclic, and (g) --C(O)NH--CH(R 14)--C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) --L 4 --N(R 5)--L 5 --, (b) --L 4 --O--L 5 --, (c) --L 4 --S(O) n --L 5 -- (d) --L 4 --L 6 --C(W)--N(R 5)--L 5 --, (e) --L 4 --L 6 --S(O)m--N(R 5)--L 5 --, (f) --L 4 --N(R 5)--C(W)--L 7 --L 5 --, (g) --L 4 --N(R 5)--S(O) p --L 7 --L 5 --, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.